Survival of human glioma cells treated with various combination of temozolomide and X-rays

Rijn, J. van; Heimans, Jan J.; Berg, Jaap van den; Valk, Paul van der; Slotman, Ben J.

doi:10.1016/s0360-3016(99)00539-8

Cited by 138 publications

(68 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In certain cell lines, an enhancement of the radiation effect has been demonstrated, whereas other cell lines have shown no interaction, but merely an additive effect (78)(79)(80)(81)(82)(83).…”

Section: Temozolomidementioning

confidence: 99%

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Franken

Oei

Kok

et al. 2013

International Journal of Oncology

View full text Add to dashboard Cite

Abstract.The linear-quadratic model (LQ model) provides a biologically plausible and experimentally established method to quantitatively describe the dose-response to irradiation in terms of clonogenic survival. In the basic LQ formula, the clonogenic surviving fraction S d ̸S 0 following a radiation dose d (Gy) is described by an inverse exponential approximation:, wherein α and β are experimentally derived parameters for the linear and quadratic terms, respectively. Radiation is often combined with other agents to achieve radiosensitisation. In this study, we reviewed radiation enhancement ratios of hyperthermia (HT), halogenated pyrimidines (HPs), various cytostatic drugs and poly(ADP-ribose) polymerase-1 (PARP1) inhibitors expressed in the parameters α and β derived from cell survival curves of various mammalian cell cultures. A significant change in the α/β ratio is of direct clinical interest for the selection of optimal fractionation schedules in radiation oncology, influencing the dose per fraction, dose fractionation and dose rate in combined treatments. The α/β ratio may increase by a mutually independent increase of α or decrease of β. The results demonstrated that the different agents increased the values of both α and β. However, depending on culture conditions, both parameters can also be separately influenced. Moreover, it appeared that radiosensitisation was more effective in radioresistant cell lines than in radiosensitive cell lines. Furthermore, radiosensitisation is also dependent on the cell cycle stage, such as the plateau or exponentially growing phase, as well as on post-treatment plating conditions. The LQ model provides a useful tool in the quantification of the effects of radiosensitising agents. These insights will help optimize fractionation schedules in multimodality treatments.

show abstract

Section: Temozolomidementioning

confidence: 99%

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Franken

Oei

Kok

et al. 2013

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…It also suggests that introducing chemotherapy early in the disease course is of importance in order to give the drug time to act against this fast-growing tumor. Based on in vitro data, synergy between TMZ and RT is suggested [23][24][25], although the trial design did not allow distinction between the relative contribution of the concomitant treatment part and the maintenance chemotherapy cycles. The outcome of a disease previously considered to be particularly resistant to chemotherapy has been substantially improved with the addition of chemotherapy.…”

Section: Lessons From the Eortc/ncic Randomized Trialmentioning

confidence: 99%

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Stupp

Hegi

Bent³

et al. 2006

The Oncologist

370

241

View full text Add to dashboard Cite

Learning ObjectivesAfter completing this course, the reader will be able to:1. List the different major subtypes of glioma and identify the appropriate treatment strategies for patients with high-grade and low-grade gliomas.2. Discuss the available evidence for the treatment of newly diagnosed glioblastoma, anaplastic astrocytoma, and anaplastic oligodendroglioma.3. Identify approved agents and other active or investigational agents used to treat patients with newly diagnosed and recurrent glioma. shown that early neoadjuvant or adjuvant administration of procarbazine, lomustine, and vincristine chemotherapy prolongs disease-free survival; however, it has no impact on overall survival. Temozolomide, a novel alkylating agent, has shown modest activity against recurrent glioma. In combination with radiotherapy in newly diagnosed patients with glioblastoma, temozolomide significantly prolongs survival. Molecular studies have demonstrated that the benefit is mainly observed Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

“…The concomitant and adjuvant use of temozolomide with IR has been shown to modestly increase the survival of patients with newly diagnosed glioblastoma (18). Despite this success, the mechanism by which these two treatment modalities interact is not well understood (19). We have recently shown that S N 1-type alkylators, like temozolomide, block NF-nB activity by inhibiting nB-element binding (20).…”

mentioning

confidence: 99%

Adenovirally Delivered Tumor Necrosis Factor-α Improves the Antiglioma Efficacy of Concomitant Radiation and Temozolomide Therapy

Yamini¹,

Yu²,

Pytel³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Treatment of malignant glioma involves concomitant temozolomide and ionizing radiation (IR). Nevertheless, overall patient survival remains poor. This study was designed to evaluate if addition of Ad.Egr^tumor necrosis factor (TNF), a replication defective adenovector encoding a cDNA forTNF-a, to temozolomide and IR can improve overall antiglioma effect. Experimental Design: The efficacy of combination treatment with Ad.Egr-TNF, IR, and temozolomide was assessed in two glioma xenograft models. Animal toxicity and brain histopathology after treatment were also examined. In addition, in an attempt to explain the antitumor interaction between these treatments, the activation status of the transcription factor nuclear factor-nB was examined.Results: Triple therapy (Ad.Egr-TNF, IR, and temozolomide) leads to significantly increased survival in mice bearing glioma xenografts compared with dual treatment. Fifty percent of animals treated with the triple regimen survive for >130 days. Pathologic examination shows that triple therapy leads to a complete response with formation of a collagenous scar. No significant change in myelination pattern is noted after triple therapy, compared with any double treatment. Treatment of intracranial glioma bearing mice with Ad.Egr-TNF and IR leads to cachexia and poor feeding that does not improve, whereas triple therapy results in less toxicity, which improves over 21 days. Both Ad.Egr-TNF and IR activate nuclear factor-nB, and temozolomide inhibits this activity in an inhibitor of nBa (InBa)^independent manner. Conclusion: This work shows that the addition of adenoviral TNF-a gene delivery to temozolomide and IR significantly improves antiglioma efficacy and illustrates a potential new treatment regimen for use in patients with malignant glioma.

show abstract

Survival of human glioma cells treated with various combination of temozolomide and X-rays

Cited by 138 publications

References 16 publications

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Adenovirally Delivered Tumor Necrosis Factor-α Improves the Antiglioma Efficacy of Concomitant Radiation and Temozolomide Therapy

Contact Info

Product

Resources

About